drug

edoxaban tosylate

Marketedupdated 2mo ago

by Daiichi Sankyo Co Ltd

Approved

community read0 votes

indications

investigational

Atrial Fibrillation

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 18, 2026

103 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Mar 28, 2028formulationUS 91495321.7y
Mar 28, 2028formulationUS 91495321.7y
Mar 28, 2028formulationUS 91495321.7y
Apr 18, 2027compositionUS 7365205285d
Apr 18, 2027compositionUS 7365205285d
Apr 18, 2027compositionUS 7365205285d

FDA exclusivities (3)

Oct 18, 2026M-14Method (3y)103d
Oct 18, 2026M-14Method (3y)103d
Oct 18, 2026M-14Method (3y)103d

Data sources

ClinicalTrials.gov

last refreshed 50m ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying edoxaban tosylate

N/ACan the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AFwithdrawn